Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR‐mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR. Combination therapy using afatinib and cetuximab has had good results in lung tu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Oncol
Autors principals: Kudo, Kenichiro, Ohashi, Kadoaki, Makimoto, Go, Higo, Hisao, Kato, Yuka, Kayatani, Hiroe, Kurata, Yasuko, Takami, Yoichiro, Minami, Daisuke, Ninomiya, Takashi, Kubo, Toshio, Ichihara, Eiki, Sato, Akiko, Hotta, Katsuyuki, Yoshino, Tadashi, Tanimoto, Mitsune, Kiura, Katsuyuki
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467494/
https://ncbi.nlm.nih.gov/pubmed/28388009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12063
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars